Centivax

07/08/2025

Incredibly excited to share that Centivax is announcing a $45M Series A to bring our universal flu vaccine into the clinic in about 8 months.

We are thrilled to partner with such a strong syndicate of investors. The round is led by Steve Jurvetson at Future Ventures, and includes NFX, BOLD Capital Partners, Amplify Bio, Base4 Capital, Kendall Capital Partners, and others.

We are also excited to add Dr. Emilio Emini to our board. Dr. Emini has been a major contributor to the development of multiple vaccines, including Prevnar, where he was responsible for its development for both pediatric and adult prevention of pneumococcal disease.

Thank you Ryan Cross at Endpoints News for the feature!

It’s not an easy time to raise money for vaccine development, especially shots that rely on mRNA technology. But against all odds, one startup has cinched $45 million to begin ...

05/29/2025

We are so pleased to welcome Jay Danao, Principal Scientist, to our team!

Jay Danao is a scientist with extensive experience across small biotech startups and large pharmaceutical companies specializing in cell biology and advanced flow cytometry. He is an exponent for use of high-dimensional flow cytometry as a crucial technique for probing complex biological questions and is equally proficient in microscopy and numerous cell analytical techniques.
Throughout his career, Jay has been instrumental in fostering collaboration and empowering scientists to leverage advanced technologies.

At Amgen, he played a key role in enabling colleagues to utilize sophisticated tools like flow cytometry and multi-dimensional microscopy. At Chimera Bioengineering, he developed and implemented assays for proof-of-concept and mechanistic studies, significantly advancing CAR T-cell research. At 23andMe, he guided the successful integration of spectral analysis, enhancing the scope and depth of scientific inquiry.

Jay is also deeply committed to mentoring the next generation of scientists. His guidance has helped many junior scientists grow into accomplished professionals, creating a legacy of innovation and discovering.

05/20/2025

We are delighted to welcome our new Director of CMC, Atsuko Sakurai-Sangria!

Atsuko is a molecular biologist with over 12 years of experience in vaccine development within the industry. She received her Ph.D. in Pharmaceutical Sciences from Kitasato University in Tokyo, Japan. She completed her postdoctoral training at the National Institute of Dental and Craniofacial Research (NIH) in Dr. Silvio Gutkind’s laboratory, where she investigated the molecular mechanisms underlying head and neck cancer development and metastasis.

Following her transition from academia to industry, Atsuko gained extensive hands-on experience in vaccine development for emerging infectious diseases. Her areas of expertise include biologics process development, technology transfer, and CMC. She has played a pivotal role in advancing multiple vaccine candidates—including mRNA/LNP-based products—from the discovery phase to the clinic during her time at VLP Therapeutics, GSK Vaccines, and RVAC Medicines.

05/15/2025

We are so pleased to welcome our new associate scientist, Claire!

Claire Tasoff is trained in virology, microbiology, and clinical virology. She earned her Bachelor’s in Biology from Connecticut College in 2019, with a special interest in microbiology and human health. In 2020, she joined Dr. Susan Lynch’s lab at UC San Francisco, where she researched the upper airway microbiome in children with asthma. In 2023, Claire became part of the Clinical Virology team at Vir Biotechnology, where she focused on influenza therapeutics and therapeutic resistance. Driven by a passion for science, Claire is committed to improving global health outcomes.

05/14/2025

Our director of herpetology, Tim Friede, was on Late Night with Seth Meyers in a segment called “The Kind of Story We Need Right Now.”

05/06/2025

It is Centivax's mission to accelerate the world’s transition to a post-pathogen humanity.

05/03/2025

Tim Friede and Centivax on the cover of the New York Times.

05/03/2025

https://www.the-scientist.com/a-man-who-survived-hundreds-of-snakebites-helped-scientists-develop-a-potent-antivenom-72977

Using the blood of a man with a unique snakebite history, researchers developed an antivenom cocktail that neutralized toxins from some of the deadliest snakes.

05/03/2025

Dr. Glanville and Tim Friede live on CNN.

05/02/2025

Universal Antivenom May Grow Out of Man Who Let Snakes Bite Him 200 Times: Scientists identified antibodies that neutralized the poison in whole or in part from the bites of cobras, mambas and other deadly species.

Scientists identified antibodies that neutralized the poison in whole or in part from the bites of cobras, mambas and other deadly species.

04/02/2025

The hunt for a single-shot vaccine capable of providing protection against multiple deadly viruses and their variants is progressing, with a new cash injection from the Coalition for Epidemic Preparedness Innovations (CEPI).

The global vaccine research funder will award up to US $5 million to progress a pioneering pan-influenza clinical candidate developed by US-based start-up Centivax into human trials.

The $5 million project led by Centivax could help validate the potential to use the technology against strains influenza, COVID-19 and HIV.

03/11/2025

We are excited to announce our partnership with Emery Pharma. "Having a trusted partner to conduct rigorous in vitro development of our batch release potency assay is crucial for the immediate need of initiating clinical trials of our first universal vaccine candidate." -Jacob Glanville, CEO.

/PRNewswire/ -- Centivax, a biotechnology company that develops broad-spectrum vaccines to combat rapidly evolving pathogens, has announced a strategic...